IDEAYA Biosciences, Inc. — Earnings Quality Grade C
IDYA · Healthcare
Some red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR growth -83.3% vs revenue growth -70.1%
Revenue grew 3024.4% but CFFO only 71.3%
Expense Quality
No material inventory
CapEx growth -38.6% vs revenue 3024.4%. Normal
Insufficient data
Insufficient data
Cash Flow Quality
CFFO/NI = 0.63. Below 1.0
FCF is negative ($-0.1B)
Accruals ratio = -3.8%. Low accruals
Cash $0.6B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.2x. Healthy
Other assets 26.1% vs revenue 3024.4%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
No goodwill
Manipulation Score
Insufficient data
Portfolio monitoring
Monitor IDYA continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25